Metabolic tumor volume by 18 F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma

Gynecologic Oncology

Volumn 125, Issue 3, 2012, Pages 566-571

  Liu, Feng Yuan ^a   Chao, Angel ^b   Lai, Chyong Huey ^b   Chou, Hung Hsueh ^b   Yen, Tzu Chen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

18 F FDG PET CT; Distant metastasis; Endometrial carcinoma; Metabolic tumor volume; Prognosis; Total lesion glycolysis

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18; HORMONE RECEPTOR;

ADRENAL METASTASIS; ADULT; AGED; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; DISTANT METASTASIS; ENDOMETRIUM CARCINOMA; FEMALE; GLYCOLYSIS; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84861189072     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.03.021     Document Type: Conference Paper

References (43)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. P.G. Rose Endometrial carcinoma N Engl J Med 335 1996 640 649
3. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 2005 491 505
4. American Joint Committee on Cancer AJCC Cancer Staging Manual 7th ed 2010 Springer New York 403 409
5. S.N. Lewin, T.J. Herzog, N.I.B. Medel, I. Deutsch, W.M. Burke, and X. Sun Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer Obstet Gynecol 116 2010 1141 1149
6. M. Markman Hormonal therapy of endometrial cancer Eur J Cancer 41 2005 673 675
7. M.B. Thomas, A. Mariani, W.A. Cliby, G.L. Keeney, K.C. Podratz, and S.C. Dowdy Role of cytoreduction in stage III and IV uterine papillary serous carcinoma Gynecol Oncol 107 2007 190 193
8. K.K. Shih, E. Yun, G.J. Gardner, R.R. Barakat, D.S. Chi, and M.M. Leitao Jr. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma Gynecol Oncol 122 2011 608 611
9. H. Karagol, P. Saip, K. Uygun, S. Kucucuk, A. Aydiner, and E. Topuz Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma Med Oncol 23 2006 543 548
10. G. Mountzios, A. Bamias, Z. Voulgaris, A. Rodolakis, G. Vlahos, and G. Gourgoulis Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model Gynecol Oncol 108 2008 130 135
11. A. Amit, J. Schink, A. Reiss, and L. Lowenstein PET/CT in gynecologic cancer: present applications and future prospects - a clinician's perspective Obstet Gynecol Clin North Am 38 2011 1 21
12. K. Nakamura, A. Hongo, J. Kodama, and Y. Hiramatsu The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer Gynecol Oncol 123 2011 82 87
13. P. Lee, D.K. Weerasuriya, P.W. Lavori, A. Quon, W. Hara, and P.G. Maxim Metabolic tumor burden predicts for disease progression and death in lung cancer Int J Radiat Oncol Biol Phys 69 2007 328 333
14. T.H. La, E.J. Filion, B.B. Turnbull, J.N. Chu, P. Lee, and K. Nguyen Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer Int J Radiat Oncol Biol Phys 74 2009 1335 1341
15. 18F- fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma Ann Surg Oncol 17 2010 115 122
16. H.H. Chung, J.W. Kim, K.H. Han, J.S. Eo, K.W. Kang, and N.H. Park Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer Gynecol Oncol 120 2011 270 274
17. 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications Ann Surg Oncol 17 2010 2787 2794
18. 18F-FDG PET in nonsurgical patients with non-small cell lung cancer Eur J Nucl Med Mol Imaging 39 2012 27 38
19. H.H. Chung, H.W. Kwon, K.W. Kang, N.H. Park, Y.S. Song, and J.K. Chung Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer Ann Surg Oncol 2012 10.1245/s10434-011-2153-x (online first)
20. S.M. Larson, Y. Erdi, T. Akhurst, M. Mazumdar, H.A. Macapinlac, and R.D. Finn Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis Clin Positron Imaging 2 1999 159 171
21. U. Tateishi, C. Gamez, S. Dawood, H.W.D. Yeung, M. Cristofanilli, and H.A. Macapinlac Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT Radiology 247 2008 189 196
22. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma J Nucl Med 50 2009 340 347
23. 18F-FDG PET in the management of endometrial cancer Eur J Nucl Med Mol Imaging 33 2006 36 44
24. R.J. Zaino, R.J. Kurman, K.L. Diana, and C.P. Morrow The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system - a gynecologic oncology group study Cancer 75 1995 81 86
25. X. Xue, M. Kim, and R. Shore Cox regression analysis in presence of collinearity: an application to assessment of health risks associated with occupational radiation exposure Lifetime Data Anal 13 2007 333 350
26. S. Pecprelli Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium Int J Gynecol Obstet 105 2009 103 104
27. N.F. Hacker, and M. Friedlander Uterine cancer J.S. Berek, N.F. Hacker, Berek and Hacker's Gynecologic Oncology 5th ed. 2009 Lippincott Williams & Wilkins Philadelphia
28. J.N. Barlin, I. Puri, and R.E. Bristow Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis Gynecol Oncol 118 2010 14 18
29. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1983 10 17
30. J.N. Bakkum-Gamez, J. Gonzalez-Bosquet, N.N. Laack, A. Mariani, and S.C. Dowdy Current issues in the management of endometrial cancer Mayo Clin Proc 83 2008 97 112
31. R.J. Zaino, R. Kurman, D. Herbold, J. Gliedman, B.N. Bundy, and R. Voet The significance of squamous differentiation in endometrial carcinoma: data from a gynecologic oncology group study Cancer 68 1991 2293 2302
32. C.A. Hamilton, M.K. Cheung, K. Osann, L. Chen, N.N. Teng, and T.A. Longacre Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers Br J Cancer 94 2006 642 646
33. N.K. Lee, M.K. Cheung, J.Y. Shin, A. Husain, N.N. Teng, and J.S. Berek Prognostic factors for uterine cancer in reproductive-aged women Obstet Gynecol 109 2007 655 662
34. R.E. Bristow, M.J. Zerbe, N.B. Rosenshein, F.C. Grumbine, and F.J. Montz Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival Gynecol Oncol 78 2000 85 91
35. B.S. Liao, L.B. Twiggs, B.S. Leung, W.C.Y. Yu, R.A. Potish, and K.A. Prem Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma Obstet Gynecol 67 1986 463 467
36. D.C. Palmer, I.M. Muir, A.I. Alexander, M. Cauchi, R.C. Bennett, and M.A. Quinn The prognostic importance of steroid receptors in endometrial carcinoma Obstet Gynecol 72 1988 388 393
37. D. Denschlag, L. Tan, S. Patel, A. Kerim-Dikeni, L. Souhami, and L. Gilbert Stage III endometrial cancer: preoperative predictability, prognostic factors, and treatment outcome Am J Obstet Gynecol 196 546 2007 e1 e7
38. H.S. Kim, C.Y. Park, J.M. Lee, J.K. Lee, C.H. Cho, and S.M. Kim Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study Gynecol Oncol 118 2010 283 288
39. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials J Nucl Med 47 2006 1059 1066
40. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 2009 122S 150S
41. S.R. Prasad, K.S. Jhaveri, S. Saini, P.F. Hahn, E.F. Halpern, and J.E. Sumner CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques - initial observations Radiology 225 2002 416 419
42. C. Haie-Meder, R. Pötter, E. Van Limbergen, E. Briot, M. De Brabandere, and J. Dimopoulos Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV Radiother Oncol 74 2005 235 245
43. D.J. Ma, J.M. Zhu, and P.W. Grigsby Tumor volume discrepancies between FDG-PET and MRI for cervical cancer Radiother Oncol 98 2011 139 142